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Abstract 
Respiratory distress syndrome (RDS) is a common consequence of pulmonary 
immaturity in the lungs of neonates.  RDS is the result of the deficient secretion of 
endogenous surfactant, causing increased surface tension in the alveolar sacs leading to 
respiratory compromise.  RDS is more common in the preterm neonate but can be 
experienced by neonates at any gestational age.  Treatment for RDS formerly consisted of 
mechanical ventilation and oxygen therapy to treat and relieve symptoms but not the 
cause.  A new treatment method, developed largely in the 1980s and 90s is the use of 
exogenous surfactant to treat the deficiency exhibited in RDS.  The administration of 
exogenous (natural or artificial) surfactant has been shown to greatly decrease the rate of 
respiratory failure in neonates experiencing respiratory distress and has greatly increased 
their survival rate.  The current use of exogenous surfactant in neonates with RDS has 
greatly reduced the morbidity and mortality rates of neonates suffering from this disease.  
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The Utilization of Exogenous Surfactant in the Neonate 
 Respiratory distress syndrome (RDS) is a disease observed in neonates that is 
caused to pulmonary immaturity.  It is caused by the lack of an endogenous substance, 
called surfactant, normally produced by the lungs.  This substance is responsible for 
facilitating and maintaining inflation of the lower airways and diffusion of oxygen into 
the pulmonary capillaries.  Without it, breathing is nearly impossible and symptoms such 
as accessory muscle use, cyanosis, and tachypnea ensue rapidly after birth.  Former 
treatment methods consisted mostly of the use of mechanical ventilation and oxygen 
therapy; today however, treatment involves the administration of an exogenous form of 
surfactant.  The development of exogenous surfactant therapy has decreased the 
morbidity and mortality rates of neonates with RDS immensely; because of its institution 
in most neonatal care environments, RDS is rarely manifested in otherwise healthy 
neonates beyond their first few hours of life (Wrobel, 2004). 
Hyaline Membrane Disease 
 In the early 1950-1960s, a respiratory disorder, hyaline membrane disease, was 
affecting tens of thousands of premature and full term neonates each year.  With its 
pathophysiology not yet fully understood by clinicians, treatment options were minimal 
and nonspecific.  The most prominent victim of this disease was the son of President John 
F.  Kennedy and First Lady Jacquelyn Kennedy who expired two days after he was born 
five and a half weeks prematurely (Wrobel, 2004).  It was at this time that physicians and 
scientists started working together to uncover the mystery of this unidentified neonatal 
killer.   
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Respiratory Distress Syndrome 
Discovery of the Disease 
 The disease formerly known as hyaline membrane disease is now commonly 
referred to as RDS.  The original name of this mysterious disease was derived from the 
hyaline membranes found at autopsy in the lungs of neonates whose cause of death was 
unknown.  Most physicians believed these membranes were the culprits of many 
premature infant deaths.  However, their origin was unclear.  Some speculated that the 
membranes were formed from neonates aspirating amniotic fluid or milk.  Regardless of 
how they formed or where they came from, it was believed that the membranes 
themselves impeded airflow, causing the symptoms observed in many neonates, 
including circumoral cyanosis, dyspnea, retractions, and grunting (Wrobel, 2004).   
One of the major turning points in the investigation of this neonatal disease was 
when pathology studies revealed the presence of fibrinogen, a protein normally found in 
the blood, composed among the hyaline membranes.  This revealed that the membranes 
must have formed within the infant’s own body, rather than an extrinsic source.   This 
discovery shifted the research focus to the internal composition of the neonatal 
respiratory tract.  Another advancement was made in the study of this disease when 
researchers found that only infants who had taken at least a few breaths displayed these 
hyaline membranes, and such structures were never observed in the lungs of stillborn 
infants.  This suggested that the membranes were formed endogenously in the lungs as a 
result of lung injury rather than the cause of injury (Wrobel, 2004).   
Dr. Mary Ellen Avery, a pediatric resident at Johns Hopkins in the mid-1950s, 
was a pioneer of research on hyaline membrane disease.  She had observed many 
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neonates experience the same struggle to breathe and wondered what was really causing 
this terrible disease.  One discovery she uncovered was that unlike babies who died of 
other causes, those who died of hyaline membrane disease had no residual air in their 
lungs at autopsy (Wrobel, 2004).  Dr. Avery found it hard to understand this finding 
because it did not make sense that these babies whom she watched struggle for breath 
seemed to be unable to retain air.  
This question ultimately led Dr. Avery and her colleague Dr. Jere Mead to 
discover the mechanism underlying the inability of these premature infant lungs to 
expand and retain air.  An earlier discovery by physiologist John Clements of a substance 
called surfactant led Avery and Mead to conclude that hyaline membrane disease was not 
caused by the presence of something foreign but rather the absence of something 
intrinsic: endogenous surfactant (Wrobel, 2004).  Surfactant lines the alveoli in the lungs, 
which are the small air sacs responsible for perfusion and oxygen delivery to the blood 
(Davidson, London, & Ladewig, 2012).  The discovery of surfactant explained why the 
disease primarily affected premature neonates, whose lungs were not yet able to produce 
surfactant, as sufficiently as full-term neonates.  It also explained why not only breathing 
in required extra effort, but expiration did as well, leading to the infant’s inability to 
retain air.  Without this substance, the surface tension of the alveoli was too high, making 
the air spaces too unstable, causing their collapse.  This major discovery on the cause of 
respiratory distress exhibited in neonates led to a shift in research and treatment options, 
ultimately leading to the production and utilization of exogenous surfactant as the 
primary method of treatment.       
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Normal Neonatal Pulmonary and Surfactant Development  
A pregnancy is considered to be full term at 40 weeks gestation.  Infants born 
before 37 completed weeks are considered preterm.  Preterm infants are at a higher risk 
for certain problems of immaturity, including RDS, low birth weight, jaundice, 
retinopathy of prematurity, and heart murmurs among other disorders related to 
underdevelopment.  The first few hours of life, known as the neonatal transition period, is 
a critical time for the identification and treatment of various cardiovascular and 
respiratory abnormalities, where rapid intervention may be necessary.  During the 
newborn period, which is the time from birth through the twenty-eighth day of life, the 
newborn undergoes numerous physiologic adaptations in order to make the successful 
transition from intrauterine to extrauterine life.  One of the major adaptations a newborn 
must undergo is an adaptation of the respiratory system (Davidson et al., 2012).   
The respiratory system is composed of an upper and lower respiratory tract.  The 
upper airway consists of the nose, mouth, pharynx, epiglottis, larynx, and trachea and 
facilitates airflow.  When air enters the respiratory tract through the nose, it is warmed, 
moistened, and filtered by the nasal mucosa.  From there it enters the pharynx, located in 
the back of the mouth, commonly called the throat.  The pharynx terminates at the 
epiglottis, which protects the entrance to the larynx leading to the trachea.  The epiglottis 
covers the larynx during swallowing to prevent aspiration and opens to allow the passage 
of air.  Beyond the trachea is the beginning of the lower respiratory tract, which consists 
of the bronchi, bronchioles, alveolar ducts, and alveoli.  The lower respiratory tract is 
responsible for perfusion.  The lower airway, with the exception of the bronchi, is located 
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entirely inside the lung tissue.  The main stem bronchi subdivide into smaller 
bronchioles, leading to the alveolar ducts and terminating at the alveoli.   
The alveoli are small grape-like clusters of air sacs, which are the primary site of 
gas exchange (Grossman, 2014).  Gas exchange occurs at the alveolar-capillary 
membrane where the alveoli are in contact with pulmonary capillaries and transfer 
oxygen and carbon dioxide by diffusion across the membrane.  Alveoli have the natural 
tendency to collapse, as they are very unstable.  In order to keep these tiny air sacs open, 
the alveoli secret the lipoprotein surfactant to create the necessary surface tension to keep 
the alveoli patent (Eisel, 2014). Figure 1 below illustrates the human respiratory anatomy. 
Figure 1. The Human Respiratory Anatomy 
 
 
 
Figure 1. Depicts the anatomy of the upper and lower airways.  Adapted from 
“Bubbles, Babies, and Biology: The Story of Surfactant,” by S, Wrobel, 2004, The 
Federation of American Societies of Experimental Biology Journal, 18, p. 1625.  
Copied by permission from the Federation of American Societies of Experimental 
Biology.  Copyright 2016. 
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When a newborn begins his or her life as a separate being, he or she must 
immediately adapt to the extrauterine world by establishing respiratory function and 
ventilation.  This transition involves radical and rapid physiologic change.  However, 
even before these significant events occur at birth, adequate lung development depends 
on vital intrauterine factors.  During the first 20 weeks of gestation, lung development 
primarily involves differentiation of pulmonary, vascular, and lymphatic structures 
beginning with the formation of the trachea, bronchi, and lung buds at six weeks 
gestation.  By seven weeks, the diaphragm begins to form and separate the thoracic and 
abdominal cavities.  A definite shape of the lungs is observable by the twelfth week of 
pregnancy.  Before birth the fetus practices breathing movements that aid in the 
development of lung tissue and strengthen respiratory muscles.  These movements may 
begin around the seventeenth week of pregnancy and continue throughout the pregnancy.  
These breathing movements facilitate the regulation of lung fluid volume and lung 
growth.  At 24 weeks, the nostrils reopen and the alveoli appear in the lungs and begin 
producing surfactant.  At 38 weeks, the lecithin-sphingomyelin ratio, which is a 
component of surfactant, approaches 2:1, indicating that surfactant production is 
sufficient (Davidson et al., 2012).   
Alveolar duct formation begins at 20-24 weeks gestation, followed by the 
formation of primary alveoli at 24-28 weeks.  Initially, these alveolar cells begin to 
differentiate into type I cells necessary for gas exchange and type II cells that provide for 
the synthesis and storage of surfactant (Martin, 2015).  Surfactant is critical for proper 
alveolar expansion and functioning.  It is composed of surface-active phospholipids, 
lecithin and sphingomyelin, which help keep the alveolar air sacs open during gas 
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exchange (Davidson et al., 2012).  Type II cells begin to increase further between 28-30 
weeks gestation, as surfactant is produced within them.  Surfactant production peaks at 
around 38 weeks gestation and continues to be produced until the pregnancy reaches full-
term.  This is a crucial time when preterm neonates born without sufficient amounts of 
surfactant exhibit RDS symptoms as a result.  Surfactant reduces alveolar surface tension, 
making it possible for the alveoli to expand and preventing the likelihood of alveolar 
collapse.  Without surfactant, the air spaces are unstable and ineffective at facilitating 
proper airflow and oxygen uptake.  Preterm infants may also have increased respiratory 
fluid in the alveolar spaces, making effective gas exchange difficult (Martin, 2014a).   
The physiology of respiration is broken down into three phases: inspiration, 
expiration, and respiration.  Inspiration is achieved through ventilation, the movement of 
air into the lungs, while expiration is the opposite, moving air out of the lungs (Eisel, 
2014).  Inspiration and expiration are accomplished through intrathoracic pressure 
changes in response to the pressure at the airway opening.  Contraction of the diaphragm 
and intercostal muscles works to decrease intrathoracic pressure, preparing for lung 
expansion.  Naturally, gas flows from an area of higher pressure, in this case the 
atmospheric pressure outside of the body to an area of low pressure, the intrathoracic 
space.  The process of inspiration takes a higher amount of effort from the body; whereas, 
expiration is a relatively passive response.  The amount of air taken in is determined by 
the individual’s tidal volume (VT), volume of air exchanged with each breath (Eisel, 
2014).  A normal VT for an adult is about 500mL; for a neonate it is much smaller, 
measured around 5mL/kg (Alapont, Villanueva, & Benavente, 2014).  When this amount 
of air is inhaled, it moves through the bronchioles and terminates at the alveoli, which is 
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the primary site of gas exchange in the lungs.  As previously mentioned, alveoli are very 
unstable and have the tendency to collapse.  To facilitate their expansion, the alveoli 
secrete surfactant, a lipoprotein that lowers the surface tension, thus reducing the amount 
of pressure needed to inflate, making them less likely to collapse (Eisel, 2014).   
Respiration occurs at the alveolar-capillary membrane (ACM) by a process called 
diffusion.   Diffusion during respiration involves the movement of oxygen and carbon 
dioxide from an area of higher concentration to an area of lower concentration.  
Therefore, oxygen moves from the atmosphere air in the alveolar sacs where its 
concentration is higher, across the ACM and into the pulmonary capillaries where its 
concentration is lower.  At the same time, carbon dioxide diffuses from the pulmonary 
capillaries across the ACM into the alveoli where it is then expired into the atmosphere 
during exhalation (Eisel, 2014).  The oxygen is then carried by arterial blood back to the 
heart and pumped throughout the body.  The partial pressure of oxygen (PaO2) in arterial 
blood, and SaO2, the amount of oxygen bound to hemoglobin, measure the oxygenation 
of the blood.  These values are measured by pulse oximetry and arterial blood gases, 
which give a better clinical picture of the efficiency of gas, transfer in the lungs and 
overall tissue oxygenation.   
The lungs have a capacity of elastic recoil due to the elastin fibers found in the 
alveolar walls, bronchioles, and chest wall.  This elastic recoil gives lungs the tendency to 
relax after being expanded during inspiration, allowing a passive decrease in volume 
caused by increased intrathoracic pressure (Eisel, 2014).  The ease of lung elasticity 
while expanding and relaxing is driven by compliance, the distensibility of the lungs.  
When compliance is decreased, it is harder for the lungs to inflate, making inspiration 
 
EXOGENOUS SURFACTANT  12 
 
challenging.  Conditions that decrease the compliance of the lungs include those that 
increase fluid in the lungs such as pneumonia and atelectasis and conditions that make 
lung tissue less elastic such as pulmonary fibrosis (Eisel, 2014).  Conversely, compliance 
is increased when alveolar walls are damaged or when elasticity is lost, as in chronic 
obstructive pulmonary disease (Kaufman, 2014).   
Surfactant Deficiency 
Another major detriment to respiration is surfactant deficiency.  As stated above, 
surfactant is a lipoprotein produced and secreted by the alveoli to facilitate their 
expansion during gas exchange.  LaPlace’s law describes the relationship between 
inspiratory pressures and surface tension of the alveoli relative to the amount of the 
alveolar volume.  According to LaPlace’s law, the pressure (P) needed to keep the alveoli 
open is proportional to the surface tension (T) and inversely proportional to the radius of 
the alveolar volume.  It is represented by the formula, P=2T/R.  Therefore, if the surface 
area is high and the alveolar volume is small as in end-expiration, the pressure required to 
keep the alveolus open is high (Martin, 2014b).  If this high pressure cannot be reached, 
the alveolus collapses on itself and diffuse atelectasis occurs throughout the lung as more 
and more alveoli collapse occurs.  Atelectasis leads to decreased lung compliance and 
hypoxemia.  Pulmonary surfactant is the key to reducing the surface tension of the 
alveoli, and even at low volumes it can lead to a decrease in required pressure and 
maintain alveolar volume and stability (Martin, 2014b).  Figure 2 depicts the effect of 
surfactant and LaPlace’s law on the alveolus.   
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Pathophysiology of RDS   
The characteristic abnormality in the pathophysiology of RDS is surfactant 
deficiency.  The observed deficiency is a direct result of lung immaturity, as surfactant 
production is not adequate until about 35 weeks gestation (Davidson et al., 2012).  In the 
premature lung, inadequate surfactant production results in increased surface tension, 
leading to instability in the alveoli at end-expiration, decreased compliance, and resultant 
low lung volume (Martin, 2014b).  These deficiencies in lung function in turn cause 
hypoxemia due to a mismatch in ventilation and perfusion from diffuse atelectasis and 
intrapulmonary and extrapulmonary shunts (Brady, 2014).  Intrapulmonary shunts occur 
when the blood flows through the pulmonary capillaries without participating in gas 
exchange and thus is exhibited in RDS because of the damage at the ACM resulting in 
the lack of oxygenation.  Extrapulmonry shunting would be due to a patent ductus 
Figure 2. The Effect of Surfactant and LaPlace’s Law on the Alveolus 
 
Figure 2. Surfactant forms a thin film (blue) at the air-liquid interface within the alveoli, 
lowering surface tension and therefore reducing the amount of pressure required to 
maintain alveolar expansion.  Adapted from “Bubbles, Babies, and Biology: The Story of 
Surfactant,” by S, Wrobel, 2004, The Federation of American Societies of Experimental 
Biology Journal, 18, p. 1634.  Copied by permission from the Federation of American 
Societies of Experimental Biology.  Copyright 2016. 
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arteriosus, which is also common in preterm neonates experiencing RDS (Davidson et al., 
2012).   
Surfactant deficiency not only makes inspiration difficult but expiration as well.  
If a newborn’s lungs lack surfactant, their first inhalation will cause the alveoli to 
collapse during expiration due to instability of the alveoli.  Some oxygen may be 
absorbed initially by the alveoli, but only a fraction of the oxygen inhaled beyond the first 
few breaths will be absorbed.  This means that continued inspiration would require extra 
effort to force air into the collapsed alveolar sacs as if every breath were just like the first.  
The increased respiratory effort would tire out the newborn’s diaphragm and tear at the 
lung tissues, leading to inflammation (Wrobel, 2004).   
Lung inflammation and respiratory epithelial injury often accompany RDS in 
neonates and may result in pulmonary edema and increased airway resistance (Martin, 
2014b).  Similar to the pathophysiology of acute lung injury and acute respiratory distress 
syndrome in adults, RDS leads to an inflammatory response, which triggers the release of 
cytokines and other cell mediators and a mass of macrophages, neutrophils, and platelets 
to the damaged ACM (Perrin, 2014).  The damaged capillary membrane begins to leak, 
allowing protein-rich fluid to fill the collapsed alveoli, further exacerbating lung injury 
and disrupting gas exchange.  As capillary permeability continues to deteriorate, 
neutrophils attach to the damaged membrane and may cross into the alveoli.  The end 
stage of this inflammatory response is the formation of hyaline membranes in the alveoli 
and conduction pathways from the consolidation of proteins (Perrin, 2014).   
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Clinical Manifestations and Diagnosis 
 The clinical manifestations of RDS primarily arise from hypoxemia due to 
abnormal pulmonary function.  Preterm birth is most often the cause of deficient 
surfactant leading to RDS, which is why symptoms present within the first minutes to 
hours after birth.  If untreated, RDS progressively worsens throughout the first forty-eight 
hours of life (Martin, 2014b).  If neonates do not present immediately after delivery in 
respiratory distress, symptoms are likely to develop within the next few hours.  The 
neonate will exhibit signs of respiratory distress including tachypnea, nasal flaring 
(reflecting the use of accessory muscles), expiratory grunting resulting from exhalation 
through a partially closed glottis, showing decreased end-expiratory volume, intercostal, 
subxiphoid, and subcostal retractions due to decreased compliance and cyanosis due to 
pulmonary shunting.  On a physical, exam breath sounds will be decreased and pulses 
diminished.  Urine output is often low in these infants within the first 24-48 hours of life 
and pulmonary edema is present (Martin, 2014b).   
 Diagnosis is often based on the clinical picture in conjunction with characteristic 
chest x-ray and history of preterm birth.  A chest x-ray would reveal low lung volume 
and diffuse ground glass opacification resulting from atelectasis and pulmonary edema.  
Other laboratory findings frequently observed in RDS include ABGs revealing 
hypoxemia with an increasing partial pressure of carbon dioxide (PCO2) and 
hyponatremia, which may develop as the disease progresses as a result of fluid retention 
(Martin, 2014b).   
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Conventional Treatment Options 
Initial management of respiratory distress in neonates, regardless of etiology, 
often involves supplemental oxygen therapy.  Supplemental oxygen may be delivered via 
facemask, continuous positive airway pressure device (CPAP), or intubation for 
mechanical ventilation if progressive respiratory distress is observed.  Traditionally, 
noninvasive ventilation is preferred whenever possible, which makes CPAP the most 
favorable option in most neonatal intensive care units.  However, invasive ventilation is 
often necessary for preterm neonates in respiratory distress (Brown & DiBlasi, 2011).  
The goal of ventilator therapy is to prevent hypoventilation and hypoxia (Davidson et al., 
2012).   
In RDS, mechanical lung expansion via CPAP or ventilator helps move the 
remaining respiratory fluid out of the alveoli and into the interstitial spaces by providing 
continuous positive pressure or positive end expiratory pressure (PEEP).  These methods 
of mechanical ventilation work to deliver much needed oxygen to the lungs and facilitate 
gas exchange; however, they do not help the underlying issue of decreased surfactant 
production.  The goal of mechanical ventilation is to maintain oxygen saturation (SpO2) 
between 90-95%, which could be measured by continuous pulse oximetry or arterial 
blood gases (Davidson et al., 2012). 
Appropriate fluid and metabolic provision may also be necessary treatment for 
neonates with RDS; including intravenous fluids and the use of an incubator to maintain a 
neutral thermal environment to decrease the neonate’s energy requirements and oxygen 
consumption (Martin, 2014a).  Prophylactic antibiotics may also be given to reduce the 
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risk of infection or sepsis if risk factors are present.  The duration of antibiotic therapy 
would be determined by results of a blood culture and chest x-ray.   
Another conventional treatment utilized for the prevention of RDS is antenatal 
steroid therapy.  The maturation effect of steroids on the fetus is the rationale behind this 
treatment option.  Antenatal steroids have been shown to reduce the incidence of RDS in 
the low-birth-weight neonate born between 24 and 34 weeks gestation (Davidson et al., 
2012).  An amniocentesis can reveal fluid from fetal lungs that can give an indication as 
to the level of maturation achieved.  Antenatal steroid therapy should be based on the 
analysis of amniocentesis.  In a controlled trial of 213 women in spontaneous premature 
labor, betamethasone or a placebo was given at least twenty-four hours before delivery.  
Only nine percent of babies born to treated mothers exhibited RDS symptoms, while 
nearly twenty-six percent of babies born to mothers who received the placebo exhibited 
symptoms (Wrobel, 2004).   
Exogenous Surfactant 
Production 
 The first clinical trials involving exogenous surfactant began in the 1980s.  At this 
point, scientists had made rapid advancements in physiology and biochemistry that 
provided insight into the mechanisms underlying the development of RDS (Whitsett, 
2014).  Researchers also achieved a better understanding of the biochemical nature of the 
lung and the chemical makeup of endogenous surfactant (Wrobel, 2004).  Such 
knowledge was instrumental in the development of both synthetic and natural exogenous 
surfactant products.   
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Surfactant has similar components to a cell membrane in that it is primarily made 
up of proteins and phospholipids.  The most abundant constituent of surfactant is the 
saturated lipid, dipalmitoyl phosphatidylcholine (DPPC), which makes up about 45-70% 
of endogenous surfactant (Hallman et al., 1994).  DPPC acts as a stabilizing agent for a 
thin film within the alveoli at the interface of liquid and air (Whitsett, 2014).  This 
surface film is responsible for controlling surface tension.  As the lung expands, causing 
tension to rise, DPPC allows the interface to stretch in response and when the lung 
contracts during expiration, DPPC is responsible for packing in molecules more tightly, 
thus lowering surface tension and preventing alveolar collapse (Wrobel, 2004).  Based on 
the knowledge of DPPC, an aerosolized form of the lipid was developed and given to 
several neonates with RDS as a viable treatment option.  However, DPPC alone was 
shown not to be effective in eliminating symptoms entirely (Wrobel, 2004).  The problem 
with DPPC alone is that it does not rapidly absorb in the air-liquid interface in the alveoli, 
rendering it virtually ineffective (Hallman et al., 1994).   
Failure of this approach led to the investigation of the properties of other 
components of surfactant, mainly unsaturated phosphatidycholine and 
phosphatidylglycerol, which constitute about 25-45% of endogenous surfactant (Hallman 
et al., 1994).  Phosphatidylglycerol is observed in larger quantities in mature lungs than 
immature lungs.  Phosphatidylglycerol levels do not begin to rise in concentration until 
about 35 weeks gestation, and therefore, would not be as abundant in premature neonatal 
lungs.  In contrast, immature lungs contain a greater amount of phosphatidylinositol than 
mature lungs, which has indicated that it is a more immature form of the phospholipid 
component phosphatidylglycerol (Martin, 2014b).   
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Other phospholipid components of surfactant include phosphatidylethanolamine 
and sphingomyelin, a saturated phospholipid with hydrophobic properties.  The ratio of 
lecithin (collection of previously mentioned phospholipids) to sphingomyelin (L/S) is 
commonly used as an assessment tool of fetal lung maturity and is measured by 
amniocentesis.  An L/S ratio of two to one is ideal for a neonate at birth.  Any neonate 
born before a sufficient L/S ration will have varying degrees of respiratory distress 
(Davidson et al., 2012).   
Four other key components of endogenous surfactant are surfactant proteins A, B, 
C, and D (SP-A, SP-B, SP-C, SP-D).  The discovery of these proteins in endogenous 
surfactant seemed to answer the question of why previously produced exogenous 
surfactant containing mostly phospholipids such as DPPC were not effective 
replacements.  SP-B and SP-C were the first proteins to be discovered and proved to be 
hydrophobic proteins that readily bind to phospholipids (Wrobel, 2004).  The reason 
DPPC alone was not effective as an artificial exogenous surfactant was that it could not 
move rapidly enough after it was secreted to get to the air-liquid interface in the alveoli to 
control surface tension.  SP-B and SP-C are believed to work together to optimize a more 
rapid distribution and absorption of phospholipids in exogenous surfactant, allowing for 
more availability at the air-liquid interface and facilitating lower surface tension and 
greater alveolar stability (Martin, 2014b).   
SP-A and SP-D were more complicated structures to identify, but with 
advancements in molecular biology, their significance was determined.  When compared 
to other identified biological proteins, SP-A and SP-D identified closely with proteins 
called collectins, which aid the immune system (Wrobel, 2004).  SP-A was the more 
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major surfactant protein, constituting about 5% of endogenous surfactant; whereas, SP-D 
was found not only in the epithelial cells of the lungs but throughout the rest of the body, 
suggesting its immunologic function in the lungs may be more generalized than SP-A.   
SP-A is a water-soluble protein with immunologic functions, which serves as an 
innate host defense protein in the lungs (Martin, 2014b).  SP-A facilitates phagocytosis of 
microbes and their clearance from the airspace.  Premature lungs lack SP-A, increasing a 
preterm neonate’s risk for infection; however, corticosteroid therapy has shown to 
increase its production.  SP-A is not present in all forms of exogenous surfactant; though 
its function is important, it is not critical to survival (Martin, 2014b).   
There are many other minor components that make up endogenous surfactant that 
have been identified, yet their significance has not yet been determined.  Many 
components of the antioxidant defense system, prostaglandins, growth factors, hormones, 
and chemical messengers all associate with surfactant (Hallman et al., 1994).  The main 
components required of successful exogenous surfactant production include DPPC, SP-B, 
and SP-C, which are absolutely essential.  SP-A and SP-D are still considered major 
components of endogenous surfactant but not entirely crucial for effective exogenous 
surfactant solutions.   
The two initial goals of exogenous surfactant therapy are efficacy and safety.  
Other factors include minimal variation, minimal immunogenicity, sufficient resistance to 
biodegradation, and availability at reasonable cost (Hallman et al., 1994).  There are two 
types of exogenous surfactant that may be utilized: natural and synthetic.  Natural 
surfactant is derived from porcine or bovine lungs through intrapulmonary lavage or by 
mincing animal lung tissue and purified by lipid extraction, separating hydrophilic 
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components including SP-A and SP-D (Martin, 2014c).  The purified lipid preparation 
contains SP-B, SP-C, DPPC, and other neutral phospholipids.  Human surfactant may 
also be utilized and isolated in amniotic fluid from full-term fetuses.  Synthetic surfactant 
combines recombinant proteins with synthetic peptides and lipids.  Modified natural 
surfactant may also be supplemented with phospholipid equivalents or other surfactant 
components (Hallman et al., 1994).  Natural surfactants tend to have a faster action of 
onset and greater improvement in RDS symptoms than do synthetic derivatives.  Among 
the different natural surfactant derivatives there seems to be no clinically significant 
differences (Martin, 2014c). 
The Use and Administration of Exogenous Surfactant 
 Surfactant therapy is indicated for the treatment of RDS in preterm infants with 
clinical symptoms.  Research now suggests that the prophylactic use of surfactant be 
integrated into the care of the neonate at risk for RDS (Rojas-Reyes, Morley, & Soll, 
2011).  Premature neonates less than 30 weeks gestation receive the most benefit from 
prophylactic surfactant therapy.  Exogenous surfactant therapy has significantly reduced 
mortality and morbidity rates in preterm infants (Martin, 2014c).  When surfactant 
therapy is utilized, the following factors must be addressed:  
• Selection of surfactant preparation 
• Indications for surfactant therapy 
• Timing of administration 
• Technical aspects of administration  
The types of surfactant therapy available are synthetic and natural preparations.  
Both types have shown to be effective in treating RDS; however, preparations containing 
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SP-B and SP-C, which were most often naturally derived surfactant, showed faster 
improvement in the neonate and relief of respiratory distress.  Recent research has shown 
that natural preparations also contribute to lower inspired oxygen concentration (FiO2) 
and ventilator pressures, a lower rate of complications from RDS, and overall decreased 
mortality rate (Martin, 2014c).   
 Immediate stabilizing interventions are usually taken prior to the consideration of 
surfactant therapy.   These interventions almost always include the use of either 
mechanical ventilation via endotracheal tube or the use of continuous positive airway 
pressure (CPAP) shortly after birth when RDS symptoms are noted.  There is data that 
now suggests nasal CPAP (nCPAP) is just as effective as mechanical ventilation in 
premature neonates at treating and preventing RDS complications (Martin, 2014c).  Nasal 
CPAP also reduces the risk of bronchopulmonary dysplasia (BPD) by avoiding 
intubation.  The use of nCPAP is consistent with the American Academy of Pediatrics 
and the European Consensus Guidelines recommendations.  Indications for intubation of 
preterm neonates in severe respiratory distress or apnea include those who do not respond 
to nCPAP intervention alone and require 40% or higher FiO2 to maintain an oxygen 
saturation of 90%.  Nasal CPAP is often initiated in the delivery room if respiratory 
distress is present (Martin, 2014c).  Many neonatologists will use increased levels of 
PEEP and prolonged initial breaths to promote fetal lung expansion and establish 
functional residual capacity (Herting, 2013). 
 If nCPAP intervention fails, endotracheal intubation is performed immediately, 
and surfactant therapy is considered and administered once RDS diagnosis is established 
and its efficacy is recognized (Martin, 2014c).  If the neonate requires greater than 30% 
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FiO2 an additional dose of surfactant may be required, according to most clinical research 
studies (Martin, 2014c).  Surfactant is traditionally administered via intratracheal 
injection through a catheter inserted either through an endotracheal tube or orally 
introduced to the trachea (Wrobel, 2004).  When surfactant therapy is utilized, it is most 
beneficial when given within the first 30-60 minutes of life.  Earlier administration of 
surfactant therapy has shown to have better clinical outcomes than delayed administration 
including lower mortality rate and decreased risk of RDS-associated complications 
including BPD, emphysema, and pneumothorax (Martin, 2014c).   
During the administration of surfactant, oxygen saturation should be monitored, 
as desaturation may occur.  Surfactant administration may be complicated by temporary 
airway obstruction caused by over insertion of the catheter in the airway or inadvertent 
instillation only to the right stem bronchus (Martin, 2014c).  Other possible complications 
are associated with intubation and prolonged mechanical ventilation, which may cause 
pulmonary injury due to volutrauma or barotrauma.   
Presently, minimally invasive techniques for surfactant administration are being 
considered and tested, such as less invasive surfactant administration (LISA).  LISA 
advocates for prophylactic administration in the delivery suite for neonates born before 
27 weeks gestation.  At this age, the premature fetal lung is extremely susceptible to 
trauma by even short-term therapy on a mechanical ventilator; therefore, nCPAP is 
utilized immediately after birth and during surfactant administration (Herting, 2013).  
Close monitoring of neonate’s cardiovascular and respiratory efforts is crucial during this 
procedure.  If the procedure is performed beyond the first few minutes of life, peripartal 
analgesia will be lost and analgesia or sedation should be considered for the neonate if 
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significant discomfort is noted before attempting to introduce the catheter.  Otherwise, 
the majority of the time, intratracheal catheter administration is done without the use of 
analgesic medication (Herting, 2013). 
Dosing of surfactant administration varies among the available preparations.  
Suggested dosing strategies range from 50-200mg/kg, depending on the brand and 
formulation used.  Several formulations are in circulation today including synthetic 
formulations such as Surfaxin®, with an initial dosage of 5.8 mL/kg (DynaMed, 2016).  
Other forms of surfactant include those derived from the lungs of animals such as calves, 
pigs, and cows.  Infasurf® is a natural surfactant derived from calf lung lavage and has an 
initial dose of 105 mg/kg or 3mL/kg (DynaMed, 2016).  Curosurf® is a formulation of 
surfactant derived from the lungs of pigs and purified by chromatography (Hallman et al., 
1994).  The initial dosage for Curosurf® is 200 mg/kg or 2.5 mL/kg (DynaMed, 2016).  
Another commonly utilized animal formulation of surfactant, Alveofact® has an initial 
dosage of 50 mg/kg or 1.2 mL/kg (DynaMed, 2016).   
Factors such as pharmacokinetics, bioavailability, half-life and concentration in 
the epithelial lining fluid (ELF) after administration serve as determinants of dosing 
strategies (Herting, 2013).  Type II alveolar cells are responsible for the majority of the 
catabolism of exogenous surfactant.  About 3-7% of the surfactant is cleared by the 
airways and about 10-30% is taken up by alveolar macrophages.  The type II alveolar 
cells take up the remaining surfactant.  In the type II alveolar cells, catabolism of 
exogenous surfactant occurs in the lamellar bodies and is secreted back in to the ELF for 
recycling.  Recycling of exogenous surfactant incorporates the breakdown of 
phospholipids in type II cells and reuses them in the synthesis of endogenous surfactant. 
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Therefore exogenous surfactant increases the amount of endogenous surfactant, 
contributing further to alveolar stability (Hallman et al., 1994).   
Evaluation: The Impact of Exogenous Surfactant 
When exogenous surfactant is administered into the airways, it obeys the 
following pattern.  When the surfactant is administered intratracheally, it is rapidly 
distributed through the patent airways and into the airspaces.  During the next one to two 
hours after administration, the surfactant begins to concentrate in the lung parenchyma; 
therefore, the amount of surfactant that can be lavaged from the airways decreases.  From 
there, the surfactant continues to congregate in the lung parenchyma and begins to flow 
into the ELF where absorption occurs and recycling begins.  Because surfactant is applied 
directly to the airways, it does not readily diffuse into the blood stream and therefore 
blood levels of the drug have little clinical importance.  Only a small amount of 
surfactant components may enter circulation due to high permeability and possible 
pulmonary edema (Hallman et al., 1994).   
In studies of exogenous surfactant administered to rabbits, maturity-dependent 
differences were recognized, suggesting the same could occur in humans.  In adult 
rabbits, 80% of exogenous surfactant became tissue-associated within less than two hours 
and about 75% of DCCP was degraded within 24 hours.  In contrast, full-term newborn 
rabbits exhibited about 50% tissue-association and a degradation rate of about 16% 
within 24 hours.  Ventilation may have increased both the degradation rate and tissue-
association rate in these animals.  These conclusions suggest that a higher dosage would 
be required for more developed neonates with RDS symptoms (Hallman et al., 1994).   
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Other factors influencing the bioavailability of exogenous surfactant include: the 
method of administration, stage and severity of pulmonary disease, and properties of 
specific type of surfactant such as carrier volume and biophysical properties (Hallman et 
al., 1994).  Generally, about 70-90% of exogenous surfactant administered via bolus-
injection through an endotracheal tube reaches the distal airways and alveoli (Dargaville, 
2012).  A small amount of surfactant may remain in the central airways or may be 
regurgitated.  Positioning the neonate on his or her right and left sides, alternating every 
few minutes during and after surfactant administration, allows gravity to assist in 
distribution, reducing the chances of unequal distribution within the lung fields (Hallman 
et al., 1994).  Additionally, repeat dosing of surfactant has been shown through numerous 
clinical trials to sustain the initial response to the drug in the neonate.  Giving multiple 
doses of surfactant has been shown to decrease the risk of pneumothorax and other 
pulmonary complications with a clearer clinical outcome expected (Soll & Ozek, 2009).   
Further Research 
Administration Techniques: Aerosolization 
Research involving exogenous surfactant in the treatment of RDS continues 
today, and focuses on aspects such as formulation, administration, and indications.  
Administration methods have an impact on the amount of exogenous surfactant utilized 
by the body and the accuracy of dosing strategies.  Current administration techniques 
include administration with the use of an aqueous carrier, as a dry powder inhalation, and 
direct endotracheal injection.  Administering surfactant with the aid of a saline-containing 
aqueous carrier increases the volume to be distributed; however, it may have a negative 
effect on pulmonary edema if it is present.  Dry-powder administration of surfactant 
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counteracts the adverse effects of carrier administration but poses the risk of inadequate 
distribution or physical obstruction.   
Under current review is the administration of surfactant through aerosolization.  
Aerosolization of surfactant may be the most superior method of administration over 
endotracheal bolus-instillation or carrier-mediated as far as equal distribution of the drug 
is considered.  However, aerosolization is associated with low bioavailability due to 
inadequate synchronization of the nebulizer with inspiration of the neonate.   
To solve this clinical problem, researchers incorporated the use of CPAP with 
aerosolized surfactant treatment (Mazela, Merrit, & Finer, 2007).  The study reported 
greater improvement in oxygenation and alveolar ventilation with the use of pharyngeal 
CPAP with aerosolized surfactant administration versus nCPAP delivery of aerosolized 
surfactant.  The reason for this discrepancy is not entirely clear and requires further 
clinical trials; however, it may be attributed to the size and clearance of the nasal 
passageways and dilation of airways.  Regardless, aerosolization of surfactant has shown 
to be more effective because of its biologic properties that enable it to distribute more 
equally among the lung parenchyma (Mazela et al., 2007). 
Pharyngeal Instillation 
In theory, the most ideal method of delivery of exogenous surfactant would be to 
instill it in the airways prior to the neonate’s first breath (Hallman et al., 1994).   
Pharyngeal instillation of exogenous surfactant prior to a neonate’s first breath has been 
undergoing clinical trials since the late 1990s.  Pharyngeal instillation is administered 
during labor before the neonate descends into the vaginal vault.  Fetal lung fluid is first 
suctioned from the airways and replaced with a surfactant-containing solution.  By 
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supplying the surfactant at the air-fluid interspace, it is presumed that the neonate will 
aspirate the surfactant containing solution, allowing its distribution to the lower airways 
(Abdel-Latif & Osborn, 2011).  This administration technique would allow the replaced 
fetal lung fluid to be the vehicle of distribution, allowing for a uniform mixing of 
surfactant in the lungs and subsequent expiration of both fetal lung fluid and excess 
surfactant upon initial aeration.  If administered before the neonate’s first breath, 
distribution would not be disturbed by hyaline membranes that form several hours to two 
days after birth in a neonate with RDS, nor would there be obstructive pulmonary lesions 
or edema to inhibit even distribution.  This technique also avoids endotracheal intubation 
and invasive mechanical ventilation, therefore reducing the risk of lung injury.  The only 
disadvantage of this technique is that it is difficult to accomplish and cannot be 
performed in any compromised labor situation that puts the mother or neonates life at risk 
(Abdel-Latif & Osborn, 2011).    
Dosing Strategies 
Another clinical question regarding the administration of surfactant in neonates 
with RDS is whether multiple or single doses of exogenous surfactant are more beneficial 
to the neonate.  While a single dose of surfactant may relieve respiratory distress 
symptoms initially, researchers investigated the use of multiple doses in neonates as 
protocol treatment.  A randomized controlled trial performed by Roger Soll and Eren 
Ozek (2009) involved two groups of neonates, group one consisted of neonates with 
established respiratory distress and group two consisted of neonates at high risk for 
respiratory distress.  In both research groups, neonates showed greater improvements in 
oxygenation and ventilator requirements and a decreased risk for pneumothorax with 
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trends toward improved survival.  Giving multiple doses of surfactant to neonates with 
RDS symptoms appears to be the most effective treatment modality as it leads to 
improved clinical outcomes (Soll & Ozek, 2009). 
Prophylactic Administration 
 Typically, the treatment for diseases such as RDS begins only after the patient 
exhibits symptoms.  One treatment option for neonates at high risk for RDS includes the 
antenatal administration of steroids to encourage maturation of the unborn infant's 
respiratory system.  Another method of prophylactic treatment under current review is the 
administration of exogenous surfactant prophylactically rather than selectively.  The 
theory behind prophylactic administration would be to treat the known cause of RDS in 
neonates at high risk and thus prevent symptoms from ever occurring, thus decreasing 
neonatal mortality and morbidity.  The prophylactic administration of surfactant was 
studied in both the term and preterm infant and reviewed by Rojas-Reyes, Morley, and 
Soll through the Cochrane Neonatal Review Group.  Results of the multiple reviewed 
clinical trials showed significantly decreased risk of pulmonary complications associated 
with RDS including pneumothorax, interstitial emphysema, bronchopulmonary dysplasia, 
or death in comparison to selectively treated neonates with established RDS symptoms 
(Rojas-Reyes, Morley, & Soll, 2012).    
Ethical Discussion 
  Within the last few decades, advancements in medicine and technology have 
greatly impacted the management of care of the critically ill neonate.   Developments in 
treatment modalities currently being incorporated into the plan of care of severely ill and 
premature neonates have demonstrated an overall decrease in morbidity and mortality 
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rates (Strandås & Fredriksen, 2015).  The life of the critically ill infant often involves 
spending months in a neonatal intensive care unit, surrounded by medical staff, 
ventilators, incubators, and other medical equipment being utilized to save or prolong 
their life.  Unable to speak for themselves, parents are required to make decisions on the 
infant’s behalf, taking into account his or her moral rights and the healthcare team’s duty 
to protect.   
 Preterm and critically ill infants have long been the subjects of medical research 
(Strandås & Fredriksen, 2015).  Within the context of exogenous surfactant therapy, 
ethical issues can arise concerning neonatal involvement in clinical trials of the drug 
involving new administration methods, dosing strategies, and formulations.  The question 
of when to initiate treatment involves a rapid and complex assessment of the risk versus 
benefit.  The ethical principle of nonmaleficence is most often in question among these 
various research studies and clinical trials as to whether their outcomes are more 
concerned with the life of the neonate it involves or the efficacy of a newly developed 
treatment method (Strandås & Fredriksen, 2015).   
 An important part of the ethical treatment of critically ill neonates lies within the 
advocating powers of the nurse.  The nurse’s role is to advocate for his or her patient, not 
only in the everyday decisions but also often in those involving life-or-death measures.  It 
is the nurse’s responsibility and duty to protect their patient from mistreatment, harm, and 
neglect (Strandås & Fredriksen, 2015).  In the neonatal intensive care unit the nurse is 
responsible for the hands-on care of the neonate.  They communicate with the entire 
healthcare team and work to support the parents through many tough decisions.  Nurses 
should be up to date on the latest medical advancements and treatment methods in order 
 
EXOGENOUS SURFACTANT  31 
 
to effectively advocate for their patient.  Ethically appropriate care should be the goal of 
all treatment modalities and nursing interventions, taking into account the risks, benefit, 
moral rights and duty to protect.   
Conclusion 
 Today, thanks to much advancement in technology, knowledge, and research in 
exogenous surfactant therapy, RDS is an uncommon cause of death among neonates in 
developed nations.  Annual death rates from RDS have decreased from 10,000-15,000 
babies annually in the United States in the 1950s and 1960s to fewer than 1,000 deaths in 
neonates annually (Whitsett, 2014).   In the midst of incredible scientific discovery, the 
story of surfactant continues to unfold with new research aiming to answer the questions 
of why some babies continue to die each year from RDS, including full-term neonates, 
and what other diseases exogenous surfactant therapy may be useful in treating.  
Surfactant therapy, in many ways has provided the opportunity of life to babies who 
otherwise may not have survived.  This discovery has demonstrated a positive and 
perpetual impact on past decades and will for generations to come. Surfactant therapy is 
truly life saving and should be properly implemented in the neonatal care environment as 
often and as appropriately as possible.  
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